Skip to content
  • Follow Us
CarboHyde
  • Home
  • Cyclodextrin Masterclass VI
  • About Us
  • Pipeline
  • CarboHyde’s Blog
  • News
  • Listen to the Carbohydrate Chronicles Podcast!
    • Carbohydrate Chronicles Season 2 / Ep 1 Application beyond pharma
    • Carbohydrate Chronicles Season 2 / Ep 2 Cyclodextrin in biologic formulation
    • Carbohydrate Chronicles Season 2 / Ep 3 Safety and toxicity
    • Carbohydrate Chronicles Season 2 / Ep 4 Cyclodextrin in food and nutraceuticals
  • Home
  • Cyclodextrin Masterclass VI
  • About Us
  • Pipeline
  • CarboHyde’s Blog
  • News
  • Listen to the Carbohydrate Chronicles Podcast!
    • - Carbohydrate Chronicles Season 2 / Ep 1 Application beyond pharma
    • - Carbohydrate Chronicles Season 2 / Ep 2 Cyclodextrin in biologic formulation
    • - Carbohydrate Chronicles Season 2 / Ep 3 Safety and toxicity
    • - Carbohydrate Chronicles Season 2 / Ep 4 Cyclodextrin in food and nutraceuticals
CarboHyde
  • Home
  • Cyclodextrin Masterclass VI
  • About Us
  • Pipeline
  • CarboHyde’s Blog
  • News
  • Listen to the Carbohydrate Chronicles Podcast!
    • Carbohydrate Chronicles Season 2 / Ep 1 Application beyond pharma
    • Carbohydrate Chronicles Season 2 / Ep 2 Cyclodextrin in biologic formulation
    • Carbohydrate Chronicles Season 2 / Ep 3 Safety and toxicity
    • Carbohydrate Chronicles Season 2 / Ep 4 Cyclodextrin in food and nutraceuticals

Oculis announces us public listing on NASDAQ

Mar 6, 2023adminEgyéb kategória

Oculis a company developing among others CD-based ophthalmic formulations, the pioneer in applying GCD nanoparticles for drug delivery to the back of the eye, announces getting listed on Nasdaq.
This tells me that we have to believe in our inventions and ideas just as Thorsteinn Loftsson and Einar Stefansson did and be persistent in working on them. And that cyclodextrins have a bright future ahead 🙂

See the press release here.

Prev
Next
Developed by Shuttle Themes. Powered by WordPress.
  • Contact Us
  • LinkedIn
  • Twitter
  • Privacy Policy